Bavarian Nordic A/S ((BVNRY)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Bavarian Nordic A/S is conducting an open-label, multicenter study titled ‘Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections.’ The study aims to evaluate the immunogenicity and safety of the MVA-BN vaccine in children compared to adults, which is significant for expanding preventive measures against smallpox, mpox, and related infections.
Intervention/Treatment: The intervention being tested is the MVA-BN vaccine, a drug administered in two doses four weeks apart. Its purpose is to prevent infections caused by smallpox, mpox, and related orthopoxviruses.
Study Design: This Phase 2 interventional study follows a single-group assignment model with no masking, focusing primarily on treatment. All participants will receive the same vaccine regimen to assess immune response and safety.
Study Timeline: The study began on July 31, 2024, with primary completion expected soon. The latest update was on February 25, 2025, indicating ongoing recruitment and progress.
Market Implications: The successful development of the MVA-BN vaccine could positively impact Bavarian Nordic’s stock performance by enhancing its product portfolio. Given the rising concern over orthopoxvirus infections, this study’s progress may influence investor sentiment favorably, especially in comparison to competitors focusing on similar vaccines.
The study is currently ongoing, with further details available on the ClinicalTrials portal.